Top Markets
#1 GALA GALA +31.36%
#2 Fabric Protocol Fabric Protocol +30.87%
#3 Bitcoin Cash Bitcoin Cash +30.67%
#4 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +30.64%
#5 Tutorial Tutorial +30.38%
#6 GoPlus Security GoPlus Security +25.74%
#7 Zora Zora +24.48%
#8 Talus Network Talus Network +24.40%
#9 aPriori aPriori +23.76%
#10 Kamino Kamino +23.25%
Coin of the day
GALA GALA
Settings
Language
ENGLISH
Currency
USD
Theme
Dechra Pharmaceuticals PLC Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

DPH
Rank in Stocks #24496
Dechra Pharmaceuticals PLC is a veterinary-focused enterprise dedicated to the... Dechra Pharmaceuticals PLC is a veterinary-focused enterprise dedicated to the development, production, regulatory approval, marketing, and distribution of animal health products and associated goods for veterinarians. The company's activities are organized across three key segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceutical Research and Development. It supplies a broad range of veterinary treatments, encompassing endocrinology, dermatology, pain management and anesthetics, cardiovascular therapies, and critical care solutions for dogs and cats. For poultry, pigs, and cattle, offerings include water-soluble antibiotics, avian vaccines, and pain relief products. Equine health is addressed with products for lameness and pain. Furthermore, Dechra offers specialized pet nutrition designed to support therapeutic conditions in cats and dogs, such as allergies, obesity, and heart or kidney diseases. Its diversified operations also involve the distribution of veterinary pharmaceuticals and equipment, the provision of financial services, the promotion of pet food, and the creation, regulation, manufacturing, and commercialization of crop protection items. The company’s merchandise is primarily channeled to customers via extensive wholesaler and distributor networks. Founded in 1997 and headquartered in Northwich, UK, Dechra Pharmaceuticals PLC operates globally, with a significant presence in the United Kingdom, Germany, across Europe, the United States, and international markets.
Share Price
$52.60
Last synced: 2024-01-15
Market Cap
$59.92M
Change (1 day)
6.81%
Change (1 year)
0.00%
Country
GB
Trade Dechra Pharmaceuticals PLC (DPH)

Category

Healthcare
P/E ratio for Dechra Pharmaceuticals PLC (DPH)
P/E ratio as of 2026 TTM: 0
According to Dechra Pharmaceuticals PLC latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Dechra Pharmaceuticals PLC from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 39.54 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.10 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 70.28 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 107.81 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.